Rising Biosciences (Rising Biosciences) Preferred Dividends : $0.00 Mil (TTM As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Rising Biosciences's preferred dividends for the three months ended in . 20 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Rising Biosciences Preferred Dividends Historical Data

The historical data trend for Rising Biosciences's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Preferred Dividends Chart

Rising Biosciences Annual Data

Trend

Preferred Dividends

Rising Biosciences Quarterly Data

Preferred Dividends

Rising Biosciences Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Rising Biosciences (GREY:RBII) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Preferred Dividends

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.